You are here

  • Home
  • Archive
  • Volume 24, Issue 2
  • Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

Article metrics

Article menu
Download PDFPDF
Basic Science
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

 

Online download statistics by month:

Online download statistics by month: February 2019 to April 2024

AbstractFullPdf
Feb 2019600
Mar 20193800
Apr 20191600
May 20192200
Jun 20192500
Jul 20191401
Aug 20191000
Sep 20191401
Oct 20191802
Nov 2019900
Dec 20192104
Jan 20204000
Feb 20201000
Mar 20202000
Apr 20204300
May 20202900
Jun 20204000
Jul 20202400
Aug 20201800
Sep 20202200
Oct 2020800
Nov 2020800
Dec 20201900
Jan 20211600
Feb 20211201
Mar 20211200
Apr 20211001
May 2021400
Oct 20211400
Nov 20211600
Dec 20215600
Jan 20222200
Feb 20222000
Mar 20221600
Apr 20221100
May 20225500
Jun 20224200
Jul 20223400
Aug 20223700
Sep 20223601
Oct 20224500
Nov 20222400
Dec 20222000
Jan 2023800
Feb 20236500
Mar 2023800
Apr 20231200
May 20231200
Jun 20232200
Jul 20231000
Aug 20232600
Sep 20231500
Oct 20232200
Nov 20231700
Dec 20235500
Jan 20243000
Feb 20244500
Mar 20245200
Apr 20243200
Total1407011